Tevogen (TVGN) Liabilities and Shareholders Equity (2021 - 2026)

Tevogen Bio Holdings (TVGN) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $4.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 20.81% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 19.37% YoY) and the FY2025 annual result came in at $4.4 million, up 26.61% from the prior year.
• Liabilities and Shareholders Equity advanced to $4.9 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $357.1 million in Q4 2022 to a low of $3.3 million in Q2 2024.
• A 5-year average of $90.5 million and a median of $4.9 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 98.46% — and 2025, when it rose 28.97%.
• Tracing TVGN's Liabilities and Shareholders Equity over 5 years: stood at $357.1 million in 2022, then tumbled by 98.46% to $5.5 million in 2023, then plunged by 37.12% to $3.5 million in 2024, then advanced by 26.61% to $4.4 million in 2025, then climbed by 12.27% to $4.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.9 million (Q1 2026), $4.4 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.